The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus

Thrombosis Research

Volumn 81, Issue 3, 1996, Pages 327-337

  De la Cruz, J P ^a   Moreno, A ^a   Merida F ^a   Garcia Campos J ^a   Sanchez De La Cuesta F ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Diabetic retinopathy; Platelets; Prostacyclin; Pyrimido pyrimidine derivatives; Thromboxane

Indexed keywords

4,8 BIS(DIETHYLAMINO) 2,6 BIS(2 HYDROXYETHYL 2 METHOXYETHYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 6 OXOPROSTAGLANDIN F1 ALPHA; DIPYRIDAMOLE; MOPIDAMOL; PROSTACYCLIN; STREPTOZOCIN; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINOPATHY; THROMBOCYTE AGGREGATION;

EID: 0029975109     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(96)00004-7     Document Type: Article

References (36)

1. CLEMENTS, RS and BELL, DSH. Complications of diabetes. Am J Med 79, 2-7, 1985.
2. DYCK, PJ. New understanding and treatment of diabetic neuropathy. N Engl J Med 326, 1287-1288, 1992.
3. DAVI, G., CATALANO, I., AVERNA, M., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322, 1769-1774, 1990.
4. HALUSHKA, P.V., LURIE, D. and COLWELL , J.D. Increased synthesis of prostaglandin E-like material by platelets from patients with diabetes mellitus. N Engl J Med 297, 1306-1312, 1977.
5. JOHNSON, M., HARRISON, H.E., HAWKER, R. and HAWKER, L. Platelet abnormalities in experimental diabetes [Abstract]. Thromb Haemostas 42, 333, 1979.
6. MULHRAD, A., ELDOR, A. and BAR-ON, H. The distribution of platelet contractile proteins in normal and streptozotocin rats. Thromb Res 14, 621-626, 1979.
7. MUSTARD, J.F. and PACKHAM, M.A. Platelet and diabetes mellitus [Editorial]. N Engl J Med 297, 1345-1350, 1987.
8. PAGANI, A., GRECO, G., TAGLIAFERRO, V., MARENA, S. and PAGANO, G. Dipyridamole administration in insulin-dependent diabetics with background retinopathy: a 36-months follow-up. Curr Ther 45, 1-7, 1989.
9. DAMAD STUDY GROUP. Effect of aspirin alone or aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 38, 491-498. 1989.
10. ESMATJES, E., MASERA, M., GALLEGO, M., COVES, M.J. and CONGET, I. Effect of the treatment with an inhibitor of platelet aggregation on the evolution of background retinopathy: 2 years of follow-up. Diabetes Res Clin Pract 7, 285-291, 1989.
11. TIMAD STUDY GROUP. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 108, 1577-1583. 1990.
12. BELLIDO, I., DE LA CRUZ, J.P. and SANCHEZ DE LA CUESTA, F. The pyrimidopyrimidine derivative RA-642, a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes. Meth Find Clin Exp Pharmacol 13, 371-375. 1991.
13. GRESELE, P., ZOJA, C., DECKMYN, H., ARNOUT, J., VERMYLEN, J. and VERTRAETE, M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemostas 50, 852-856, 1983.
14. DE LA CRUZ, J.P., SINTAS, A., MORENO, A., GARCIA-CAMPOS, J. and SANCHEZ DE LA CUESTA, F. Dipyridamole and RA-642 inhibit the production of superoxide anion and free radical damage to rat lens. Pharmacol Toxicol 69, 201-204, 1991.
15. DE LA CRUZ, J.P., MORON, D. and SANCHEZ DE LA CUESTA, F. Antiplatelet effect of the pyrimido-pyrimidine derivative RA-642. Thromb Res 63, 463-468, 1991.
16. DE LA CRUZ, J.P., VILLALOBOS, M.A., CARRASCO, T., SMITH-AGREDA, J.M. and SANCHEZ DE LA CUESTA, F. The pyrimido-pyrimidine derivative RA-642 protects from brain injury in a combined model of permanent focal ischemia and global ischemia-reperfusion. Brain Res 597, 250-256, 1992.
17. DE LA CRUZ, J.P., ORTEGA, G. and SANCHEZ DE LA CUESTA, F. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity. Biochem Pharmacol 47, 209-215, 1994.
18. WALLOW, I.H.I. and ENGERMAN, R.L. Permeability and patency of retinal blood vessels in experimental diabetes. Invest Ophthalmol Vis Sci 18: 447-461, 1977.
19. GONZALEZ, D. and WINTZ, A. Digital image processing. Addison Wesley Publishing Company, London (1987).
20. CARDINAL, D.C. and FLOWER, J.R. The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Meth 3, 135-158, 1980.
21. WILLIAMSON, J.R., CHANG, K. and TILTON, R.G. Increased vascular permeability in spontaneously diabetic BB/WW rats with mild severe streptozotocin-induced diabetes. Diabetes 36, 813-821, 1987.
22. GINDERDEUREN, R.P., MALCOLM, D., VARMA, D.R., ARANDA, J. and CHEMTOB, S. Dissociation between prostaglandin level and blood flow to the retina and choroid in the newborn pig after nonsteroidal antiinflammatory drugs. Invest Ophthalmol Vis Sci 33, 3378-3384, 1992.
23. PATERSON, R.A., HEATH, H. and CRANFIELD, T. The effect of O-(β-hydroxyethyl) rutoside on platelet intermediary metabolism in normal and streptozotocin diabetic rats. Biochem Pharmacol 23, 1591-1594, 1984.
24. WINOCOUR, P., PERRY, D.W. and HATTON, M.W.C. The hypersensitivity to platelets from diabetic rats is not due increased thrombin binding. Thromb Res 61, 469-475, 1991.
25. DE LA CRUZ, J.P., MORENO, A., SANCHEZ DE LA CUESTA, F. and GARCÍA CAMPOS, J. Effect of antiplatelet drug therapy on the retinal vascular pattern in experimental diabetes. Can J Ophthalmol 25, 329-232, 1990.
26. MORENO, A., DE LA CRUZ, J.P., GARCÍA CAMPOS, J. and SANCHEZ DE LA CUESTA, F. Prostacyclin-thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes. Can J Ophthalmol 30: 117-123, 1995.
27. ISHII, H., UMEDA, F., and NAWATA, H. Platelet function in diabetes mellitus. Diabetes/Metabolism Rev 8: 53-66, 1992.
28. GLASSMAN, A.B. Platelet abnormalities in diabetes mellitus. AnnClin Lab Sci 23: 47-50, 1993.
29. RIFKIN, P.L. and ZUCKER, M.B. The effect of dipyridamole and RA-233 on human platelet function in vitro. Thromb Diathes Haemorrh 29, 694-700, 1973.
30. REUTER, H. The effect of the pyrimido-pyrimidine RA-233 of function and metabolism of human platelets. Acta Med Scand 190, 239-245, 1971.
31. ELIASSON, R. and BYGDEMAN, S. Effect of dipyridamole and two pyrimido-pyrimidine derivatives on the kinetics of human platelet aggregation and platelet adhesiveness. Scand J Clin Lab Invest 24, 145-151, 1969.
32. AGARWAL, K.C., BUCKLEY, R.S. and PARKS, R.E. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase, species differences. Thromb Res 47, 191-200, 1987.
33. NERI SERNERI, G.G., MASOTTI, G., ABBATE, R., et al. Enhanced prostacyclin production and decreased thromboxane formation by dipyridamole. Lancet 1, 489-494, 1979.
34. MONCADA, S. and KORBUT, R. Dipiridamol y otros inhibidores de la fosfodiesterasa actúan como agentes antitrombótico potenciando la prostaciclina endógena. Lancet (edición española) 17, 1286-1289, 1978.
35. DE LA CRUZ, J.P., MORENO, A., MERIDA, F., GARCIA CAMPOS, J.M. and SANCHEZ DE LA CUESTA. F. The pyrimido-pyrimidine derivatives, dipyridamole and RA-642 reduce opacification of crystalline lens in diabetic rats. Pharmacol Toxicol 75, 250-254, 1994.
36. KOYAMA, S. Characteristic cardiovascular effects of RA-642, a pyrimido-pyrimidine derivative in anesthetized dogs. J Pharmacol Exp Ther 233, 480-484, 1985.